GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
89.79
-0.50 (-0.55%)
At close: Jul 2, 2025, 4:00 PM
89.76
-0.03 (-0.03%)
After-hours: Jul 2, 2025, 7:55 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $87.12M in the quarter ending March 31, 2025, with 39.56% growth. This brings the company's revenue in the last twelve months to $330.14M, up 48.81% year-over-year. In the year 2024, GeneDx Holdings had annual revenue of $305.45M with 50.79% growth.
Revenue (ttm)
$330.14M
Revenue Growth
+48.81%
P/S Ratio
7.46
Revenue / Employee
$330,143
Employees
1,000
Market Cap
2.56B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
WGS News
- 7 days ago - GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics - Business Wire
- 9 days ago - GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability - Business Wire
- 16 days ago - WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 5 weeks ago - GeneDx to Participate in Upcoming Investor Conferences - Business Wire
- 5 weeks ago - GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale - Business Wire
- 6 weeks ago - GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip - Seeking Alpha
- 7 weeks ago - GeneDx: Time To Buy The Dip - Seeking Alpha
- 2 months ago - GeneDx Announces Completion of Fabric Genomics Acquisition - Business Wire